Core Viewpoint - Yingjian Medical (01419) reported a mid-term performance for the six months ending December 31, 2025, showing a revenue of approximately HKD 342 million, representing an increase of about HKD 26.6 million or 8.4% compared to the mid-term of the 2025 fiscal year [1] Financial Performance - The profit attributable to the company's owners was approximately HKD 18.3 million, an increase of about HKD 1.5 million or 8.5% from approximately HKD 16.8 million in the mid-term of the 2025 fiscal year [1] - Basic earnings per share were approximately HKD 0.048 [1] Revenue Growth Drivers - The revenue growth from the group's general medical services was primarily due to an increase in patient visits, which was offset by a decrease in average spending per visit [1]
盈健医疗发布中期业绩 股东应占溢利约1830万港元 同比增加8.5%